A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease (RETHINK-ALZ)

  • STATUS
    Recruiting
  • End date
    Oct 10, 2023
  • participants needed
    750
  • sponsor
    Cassava Sciences, Inc.
Updated on 10 October 2022
dementia
mini-mental state examination
alzheimer's disease

Summary

A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 weeks. Approximately 750 participants will be randomized (1:1) to receive either placebo or 100 mg tablets of simufilam, twice daily, for 52 weeks. Clinic visits will occur 4 weeks after the baseline visit, and then every 12 weeks until the end of the study. The safety of simufilam, and its efficacy in enhancing cognition and slowing cognitive and functional decline will be evaluated.

Description

The primary objective of this study is to investigate the safety and efficacy of simufilam (PTI-125) in enhancing cognition and slowing cognitive and functional decline following 52-week, repeat-dose oral administration in participants with mild-to-moderate AD. Secondary objectives include the assessment of simufilam's effect on neuropsychiatric symptoms and caregiver burden. A third objective is to investigate the effect of simufilam treatment on plasma biomarkers. A limited number of research sites will be invited to participate in the pharmacokinetic (PK) and plasma biomarker sub-study. Collection of PK samples will enable an exposure-response analysis. Approximately 100 subjects will participate (50 per group). Plasma samples will be collected during the Screening Visit and again at Weeks 28 and 52. Change from baseline for plasma biomarkers represent additional secondary endpoints.

Safety will be evaluated by adverse event monitoring, vital signs, clinical labs, and the Columbia Suicide Severity Rating Scale at every visit. All subjects will undergo magnetic resonance imaging during screening to ensure entry criteria are met. Electrocardiograms will be conducted on Day 1 and Weeks 4, 28, and 52. A complete physical and neurological examination will be performed at screening, and brief examinations will be performed at all other visits. Weight will be measured during the Screening Period, on Study Day 1, and at all other visits.

An independent Data Safety Monitoring Board (DSMB) will meet periodically to review subject safety assessments and determine if dosing may continue. A charter will be developed with specific guidance for the DSMB.

Details
Condition Alzheimer Disease
Treatment Placebo, Simufilam
Clinical Study IdentifierNCT04994483
SponsorCassava Sciences, Inc.
Last Modified on10 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Meets National Institute on Aging and Alzheimer's Association Research Framework criteria for individuals in clinical Stage 4 or 5 of the Alzheimer's continuum
Evidence for AD pathophysiology, confirmed either prior to or during screening
MMSE score ≥ 16 and ≤ 27 at screening
Clinical Dementia Rating - Global Score must be 0.5, 1 or 2
If receiving background AD medications, the dosing regimen must be stable for at least 12 weeks prior to randomization
The subject has been a non-smoker for at least 3 years
Availability of a study partner
Individuals who have participated in a clinical study with an investigational drug targeting the underlying AD process may be permitted to participate in this study

Exclusion Criteria

A neurologic condition other than AD that significantly contributes to the subject's dementia
Any current primary psychiatric diagnosis other than AD if it is likely to confound cognitive assessment or ability to comply with study procedures
Geriatric Depression Scale (15-item) score > 8
Suicidal ideation during the past 3 months or suicidal behavior during the past 12 months
Alcohol or substance use disorder within 2 years of screening
MRI presence of cerebral vascular or other significant pathology
History of transient ischemic attack or stroke within 12 months of screening
Seizure within 12 months of screening
Severe head trauma or head trauma considered likely to be contributing to the subject's cognitive impairment
Sleep apnea that is considered likely to be contributing to the subject's cognitive impairment
Insufficiently controlled diabetes mellitus or hypertension
Body mass index < 18.5 or > 35.0
History or diagnosis of clinically significant cardiac disease
Prescribed aducanumab
COVID-19 infection within 3 months of screening. If no history of a prior COVID-19 infection, subject must be fully vaccinated for COVID-19 at least 2 weeks prior to randomization
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note